A Novel Isocitrate Dehydrogenase 1 G131D Mutation in Glioblastoma
Glioblastoma, a highly aggressive and malignant brain tumor, remains a significant challenge in neuro-oncology. The identification of molecular markers has revolutionized the diagnosis and classification of gliomas, with isocitrate dehydrogenase (IDH) mutations playing a pivotal role in prognostic stratification. This article presents a comprehensive analysis of a novel IDH1 G131D mutation in glioblastoma, detailing the clinical, histopathological, and molecular genetic findings of the case.
Clinical Presentation and Radiologic Features
A 68-year-old male patient presented with a 2-month history of aphasia, a condition characterized by the loss of ability to understand or express speech. Magnetic resonance imaging (MRI) revealed an abnormal signal in the left temporal lobe, exhibiting heterogeneous enhancement. The imaging findings were suggestive of a glioma, prompting further diagnostic and therapeutic interventions.
Surgical Intervention and Histopathological Examination
The patient underwent total tumor resection, and the resected tissue was subjected to microscopic examination. The histopathological analysis revealed a high-grade glial tumor with several characteristic features. The tumor cells were pleomorphic, displaying elevated mitotic activity, microvascular proliferation, and pseudopalisading necrosis. Notably, a portion of the lesion contained round cells with perinuclear halos, and tumor cells were observed growing around neurons, forming secondary structures.
Immunohistochemical investigation was performed to further characterize the tumor. The tumor cells expressed glial fibrillary acidic protein (GFAP) and oligodendrocyte transcription factor 2 (Olig-2), markers indicative of glial differentiation. However, there was only focal positivity for p53 protein, with approximately 5% of tumor cells staining positive. Alpha-thalassemia/mental retardation syndrome X-linked protein expression was positive, while the tumor cells were negative for IDH1 R132H, NeuN, and H3 K27M. The Ki-67 proliferation index was approximately 20%, reflecting the tumor’s aggressive nature.
Molecular Genetic Analysis
Next-generation sequencing (NGS) analysis was conducted on formalin-fixed paraffin-embedded tumor tissues to identify molecular alterations. The NGS results revealed a heterozygous IDH1 CGT>AGT G131D mutation, a novel finding in gliomas. Additionally, the analysis identified epidermal growth factor receptor (EGFR) amplification, cyclin-dependent kinase inhibitors 2A/B (CDKN2A/B) deletion, loss of chromosome 10, and 1p loss of heterozygosity (LOH). Chromosome 19q was intact, and mutations in IDH2, H3F3A, HIST1H3B, BRAF, and TERT promoters were absent.
The IDH1 G131D mutation was confirmed by Sanger sequencing, providing robust validation of the NGS findings. Fluorescence in situ hybridization (FISH) was employed to confirm the presence of 1p/19q status and EGFR amplification. The FISH results corroborated the NGS data, demonstrating 1p LOH, intact 19q, and EGFR amplification.
Integrated Diagnosis and Classification
Based on the histopathological and molecular genetic findings, the tumor was diagnosed as glioblastoma, IDH-mutant (IDH1 G131D mutation), World Health Organization (WHO) grade IV. This classification aligns with the 2016 WHO criteria for central nervous system tumors, which emphasize the integration of molecular markers into diagnostic algorithms. The presence of IDH1 mutation, despite its novel nature, supports the diagnosis of IDH-mutant glioblastoma, a subtype associated with distinct clinical and prognostic implications.
Discussion
IDH mutations are well-established prognostic markers in diffuse gliomas, with IDH1 R132H being the most common mutation, accounting for approximately 90% of cases. The IDH1 G131D mutation represents a novel variant, expanding the spectrum of known pathogenic IDH mutations. While the functional consequences of this specific mutation remain to be fully elucidated, its identification underscores the genetic heterogeneity of gliomas and the importance of comprehensive molecular profiling in clinical practice.
The case presented here highlights several key molecular alterations commonly associated with glioblastoma, including EGFR amplification, CDKN2A/B deletion, and loss of chromosome 10. These alterations contribute to the tumor’s aggressive behavior and are integral to the molecular classification of gliomas. The absence of TERT promoter mutations and intact chromosome 19q further differentiate this case from oligodendrogliomas, which typically exhibit these features.
Therapeutic Implications and Prognosis
Post-operatively, the patient received a combination of radiotherapy and chemotherapy with temozolomide (140 mg, qd). At the 2-month follow-up, no recurrence or progression was observed. The prognostic significance of the IDH1 G131D mutation remains to be determined, as longer follow-up is required to assess its impact on clinical outcomes. However, given the favorable prognosis associated with IDH-mutant gliomas, it is plausible that this novel mutation may confer a similar prognostic benefit.
Conclusion
This case report documents the first known instance of an IDH1 G131D mutation in glioblastoma, contributing to the evolving understanding of glioma genetics. The integration of histopathological and molecular genetic findings enabled an accurate diagnosis and informed therapeutic decision-making. The identification of novel IDH mutations underscores the importance of comprehensive molecular profiling in the era of precision medicine. Further research is warranted to elucidate the functional and prognostic implications of the IDH1 G131D mutation in gliomas.
doi.org/10.1097/CM9.0000000000001172
Was this helpful?
0 / 0